leisure time -WSS

leisure time

author：focus 2025-09-06 04:41:56 - browse：37238

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Meta looks to target Twitter with a rival app called Threads

knowledge

WSS

Meta looks to target Twitter with a rival app called Threads

How to make the FDA’s new prescription one

Walmart eyes Medicare Advantage provider ChenMed

Diverse clinical trials: Why aren’t we there yet?

Will the IRA bring competition to the biologics market?

4th of July breaks record for highest global temperature ever measured

explore

leisure time

entertainment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Jerome Adams on the need for new antivirals for Covid

Diverse clinical trials: Why aren’t we there yet?

The cancer drug shortage isn’t new — and neither are the solutions

How housing is health care on Long Island

Activists slam private health insurers over coverage restrictions

New case study details death in closely watched Alzhiemer's trial

Hollywood unions extend contract negotiations for actors

How to make the FDA’s new prescription one

entertainment

Bacterial infection may be ‘key event’ in endometriosis, study says

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

Inside the fall of star MIT scientist David Sabatini

New weight loss drugs vying to be the next Wegovy or Mounjaro

Van's Gluten Free Original Waffles recalled for possible wheat allergen

New case study details death in closely watched Alzhiemer's trial

knowledge

knowledge

hotspot

focus